Safety of canagliflozin, empagliflozin and dapagliflozin for T2DM patients: a network meta-analysis

Wenqiang KONG; Lu WEN; Chunyan ZHANG; Biao DU

doi:10.16016/j.1000-5404.201804062

您当前的位置：

首页 >

文章列表页 >

Safety of canagliflozin, empagliflozin and dapagliflozin for T2DM patients: a network meta-analysis

Clinical Medicine | 更新时间：2026-01-09

- Safety of canagliflozin, empagliflozin and dapagliflozin for T2DM patients: a network meta-analysis
- Journal of Third Military Medical University Vol. 40, Issue 19, Pages: 1792-1804(2018)
- 作者机构：
  
  1.646000 四川泸州，西南医科大学药学院
  2.610072 成都，四川省人民医院药学部
  3.637000 四川南充，川北医学院药学院
  4.4040004 重庆万州，重庆三峡中心医院药学部
- 作者简介：
- 基金信息：
  
  the Special Project of Science and Technology Innovation for Social Undertaking and Livelihood Security of Chongqing(CSTC2015shmszx120073);the Special Project of Science and Technology Innovation for Social Undertaking and Livelihood Security of Chongqing(CSTC2017shmsA130105);the Fund of Sci & Tech Plan of Wanzhou District, Chongqing(201403055)
- DOI：10.16016/j.1000-5404.201804062
  CLC： R587.1;R589.1
- Received：06 April 2018，
  
  Revised：2018-07-06，
  
  Published：15 October 2018
- 稿件说明：
移动端阅览
Wenqiang KONG, Lu WEN, Chunyan ZHANG, et al. Safety of canagliflozin, empagliflozin and dapagliflozin for T2DM patients: a network meta-analysis[J]. Journal of Third Military Medical University, 2018, 40(19): 1792-1804.
DOI：

Wenqiang KONG, Lu WEN, Chunyan ZHANG, et al. Safety of canagliflozin, empagliflozin and dapagliflozin for T2DM patients: a network meta-analysis[J]. Journal of Third Military Medical University, 2018, 40(19): 1792-1804. DOI： 10.16016/j.1000-5404.201804062.

摘要

目的

采用Meta分析研究评价卡格列净、恩格列净、达格列净治疗2型糖尿病患者的安全性。

方法

检索PubMed、CENTRAL、Embase数据库，检索时限从建库到2018年1月，纳入有关RCT文献，传统Meta分析和网状Meta分析用STATA14完成。

结果

共纳入34篇文献，含21 216名患者的35项RCT。Meta分析结果显示，卡格列净、恩格列净、达格列净与安慰剂和阳性药物相比：①均不会增加因不良反应退出人数，差异无统计学意义(

0.05)；②能够显著增加生殖器感染的人数，且女性感染人数要明显多于男性，差异均有统计学意义(

0.05)；③仅达格列净可轻微增加尿路感染人数[

=1.26，95%

(1.02~1.55)，

=0.039

]

。④卡格列净与恩格列净[

=1.53，95%

(1.02~2.30)

0.05

]

、安慰剂[

=1.74，95%

(1.32~2.30)

0.05

]

相比，明显增加了低血糖发生人数。⑤恩格列净和达格列净与DPP-4抑制剂、GLP-1激动剂、二甲双胍

、安慰剂相比，低血糖发生人数差异无统计学意义(

0.05)。

结论

卡格列净、恩格列净、达格列净治疗2型糖尿病，仅增加生殖器感染人数，有较好的耐受性和安全性；3种药物中恩格列净耐受性和安全性可能最好。

Abstract

Objective

To evaluate the safety of canagliflozin

empagliflozin and dapagliflozin in treatment of type 2 diabetes mellitus (T2DM) by network meta-analysis.

Methods

The databases including PubMed

Embase

and CENTRAL from inception to January 2018 were searched for eligible randomized controlled trials (RCTs) evaluating the SGLT2 inhibitors in T2DM patients. Conventional meta-analysis and network meta-analysis were performed by STATA14.

Results

A total of 34 studies

including 35 RCTs

involving 21 216 patients were collected. Meta-analysis showed that when compared with placebo and positive agents: ① the 3 drugs didn't increase the number of patients who required discontinuation due to adverse events (

0.05); ② they significantly increased the number of genital infections

especially in women

with significant differences (

0.05). ③ Only dapagliflozin slightly raised the number of urinary tract infections (UTIs) (

=1.26

95%

: 1.02~1.55

=0.039); ④ Compared with empagliflozin (

=1.53

95%

: 1.02~2.30

0.05) and placebo (

=1.74

95%

: 1.32~2.30

0.05)

canagliflozin slightly increased the incidence of hypoglycemia; ⑤ Empagliflozin and dapagliflozin didn't increase the incidence of hypoglycemia

when compared with DPP-4 inhibitors

GLP-1 agonists

metformin and placebo (

0.05).

Conclusion

Canagliflozin

empagliflozin and dapagliflozin show better tolerance and safety

though increasing the risk of genital infections in treatment of T2DM. Among them

empagliflozin may be the best in tolerance and durability.

关键词

Keywords

references

[Executive summary: Standards of medical care in diabetes—2012[J ] . Diabetes Care, 2012, 35(Suppl 1): S4-S10. DOI: 10.2337/dc12-s004 http://dx.doi.org/10.2337/dc12-s004 .

CHEN L, MAGLIANO D , ZIMMET P Z. The worldwide epidemiology of type 2 diabetes mellitus—present and future perspectives[J]. Nat Rev Endocrinol, 2011, 8(4): 228-236. DOI:10.1038/nrendo.2011.183.

JI L, HAN P, LIU Y, et al .Canagliflozin in Asian patients with type 2 diabetes on metformin alone or metformin in combination with sulphonylurea[J ] .Diabetes Obes Metab, 2015, 17(1):23-31. DOI: 10.1111/dom.12385

INZUCCHI S E, BERGENSTAL R M, BUSE J B, et al . Management of hyperglycaemia in type 2 diabetes: a patient- centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)[J ] . Diabetologia, 2012, 35(6): 1364-1379. DOI: 10.1007/s00125-012-2534-0

BASILE J N. The potential of sodium glucose cotransporter 2 (SGLT2) inhibitors to reducecardiovascular risk in patients with type 2 diabetes (T2DM)[J]. J Diabetes Complicat, 2013, 27(3):280-286. DOI: 10.1016/j.jdiacomp.2012.12.004

SHYANGDAN D S, UTHMAN O A, WAUGH N, et al . SGLT-2 r eceptor inhibitors for treating patients with type 2 diabetes mellitus: a systematic review and network meta-analysis[J ] . BMJ Open, 2016, 6(2):e009417. DOI: 10.1136/bmjopen-2015-009417

HIGGINS J P T, ALTMAN D G, STERNE A C. Chapter 8: Assessing risk of bias in included studies.[M]//Higgins J, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions Version 510 (updated March 2011): The Cochrane Collaboration, 2011 Accessed August 15, 2016.

HIGGINS J P, JACKSON D, BARRETT J K, et al . Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies[J ] . Res Synth Methods, 2012, 3(2): 98-110. DOI: 10.1002/jrsm.1044.

VERONIKI A A, VASILIADIS H S, HIGGINS J P, et al . Evaluation of inconsistency in networks of interventions[J ] . Int J Epidemiol, 2013, 42(1):332-345. DOI: 10.1093/ije/dys222.

CHAIMANI A, SALANTI G. Using network meta-analysis to evaluate the existence of small-study effects in a network of interventions[J]. Res Synth Methods, 2012, 3(2):161-176. DOI: 10.1002/jrsm.57.

SALANTI G, ADES A E, IOANNIDIS J P. Graphical methods and numerical summaries for presenting results from multiple- treatment meta-analysis: an overview and tutorial[J]. J Clin Epidemiol, 2011, 64(2):163-171. DOI: 10.1016/j.jclinepi.2010.03.016.

RODBARD H W, SEUFERT J, AGGARWAL N, et al . Efficacy and safety of titrated canagliflozin in patients with type 2 diabetes mellitus inadequately controlled on metformin and sitagliptin[J ] . Diabetes Obes Metab, 2016, 18(8):812-819. DOI: 10.1111/dom.12684.

NAUCK M A, DEL PRATO S, MEIER J J, et al . Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial[J ] . Diabetes Care, 2011, 34(9):2015-2022. DOI: 10.2337/dc11-0606.

HENRY R R, MURRAY A V, MARMOLEJO M H, et al . Dapagliflozin, metformin XR, or both:initial pharmacotherapy for type 2 diabetes, a randomised controlled trial[J ] . Int J Clin Pract, 2012, 66(5):446-456. DOI: 10.1111/j.1742-1241.2012.02911.x.

LEITER L A, YOON K H, ARIAS P, et al . Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin:a randomized, double-blind, phase 3 study[J ] . Diabetes Car e, 2015, 38(3):355-364. DOI: 10.2337/dc13-2762.

RIDDERSTRÅLE M, ANDERSEN K R, ZELLER C, et al . Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes:a 104-week randomised, active-controlled, double-blind, phase 3 trial[J ] .Lancet Diabetes Endocrinol, 2014, 2(9):691-700. DOI: 10.1016/S2213-8587(14)70120-2.

SCHERNTHANER G, GROSS J L, ROSENSTOCK J, et al . Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial[J ] . Diabetes Care, 2013, 36(9):2508-2515. DOI: 10.2337/dc12-2491.

STENLÖF K, CEFALU W T, KIM K A, et al . Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise[J ] . Diabetes Obes Metab, 2013, 15(4):372-382. DOI: 10.1111/dom.12054.

LAVALLE-GONZáLEZ F J, JANUSZEWICZ A, DAVIDSON J, et al . Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial[J ] . Diabetologia, 2013, 56(12):2582-2592. DOI: 10.1007/s00125-013-3039-1.

WILDING J P, CHARPENTIER G, HOLLANDER P, et al . Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial[J ] . Int J Clin Pract, 2013, 67(12):1267-1282. DOI: 10.1111/ijcp.12322.

INAGAKI N, KONDO K, YOSHINARI T, et al . Efficacy and safety of canagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled with diet and exercise: a 24-week, randomized, double-blind, placebo-controlled, Phase Ⅲ study[J ] . Expert Opin Pharmacother, 2014, 15(11):1501-1515. DOI: 10.1517/14656566.2014.935764

FORST T, GUTHRIE R, GOLDENBERG R, et al . Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone[J ] . Diabetes Obes Metab, 2014, 16(5):467-477. DOI: 10.1111/dom.12273.

BODE B, STENLÖF K, HARRIS S, et al . Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55-80 years with type 2 diabetes[J ] . Diabetes Obes Metab, 2015, 17(3):294-303. DOI: 10.1111/dom.12428.

QIU R, CAPUANO G, MEININGER G. Efficacy and safety of twice-daily treatment with canagliflozin, a sodium glucose co-transporter 2 inhibitor, added on to metformin monotherapy in patients with type 2 diabetes mellitus[J]. J Clin Transl Endocrinol, 2014, 1(2):54-60. DOI: 10.1016/j.jcte.2014.04.001.

ROSENSTOCK J, CHUCK L, GONZÁLEZ-ORTIZ M, et al . Initial combination therapy with canagliflozin plus metformin versus each component as monotherapy for drug-Naïve type 2 diabetes[J ] . Diabetes Care, 2016, 39(3): 353-362. DOI: 10.2337/dc15-1736.

RODEN M, MERKER L, CHRISTIANSEN AV, et al . Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-naïve patients with type 2 diabetes: a double-blind extension of a Phase Ⅲ randomized controlled trial[J ] .Cardiovasc Diabetol, 2015, 14:154. DOI: 10.1186/s12933-015-0314-0.

SØFTELAND E, MEIER J J, VANGEN B, et al . Empagliflozin as add-on therapy in patients with type 2 diabetes inadequately controlled with linagliptin and metformin:a 24-week randomized, double-blind, parallel-group trial[J ] .Diabetes Care, 2017, 40(2):201-209. DOI: 10.2337/dc16-1347

MERKER L, HÄRING H U, CHRISTIANSEN A V, et al . Empagliflozin as add-on to metformin in people with Type 2 diabetes[J ] . Diabet Med, 2015, 32(12):1555-1567. DOI: 10.1111/d me.12814.

HÄRING H U, MERKER L, SEEWALDT-BECKER E, et al . Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial[J ] . Diabetes Care, 2013, 36(11):3396-3404. DOI: 10.2337/dc12-2673.

KOVACS C S, SESHIAH V, MERKER L, et al . Empagliflozin as add-on therapy to pioglitazone with or without metformin in patients with type 2 diabetes mellitus[J ] . Clin Ther, 2015, 37(8):1773-1788. DOI: 10.1016/j.clinthera.2015.05.511.

DEFRONZO R A, LEWIN A, PATEL S, et al . Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin[J ] . Diabetes Care, 2015, 38(3):384-393. DOI: 10.2337/dc14-2364

LEWIN A, DEFRONZO R A, PATEL S, et al . Initial combination of empagliflozin and linagliptin in subjects with type 2 diabetes[J ] . Diabetes Care, 2015, 38(3):394-402. DOI: 10.2337/dc14-2365.

ROSENSTOCK J, JELASKA A, FRAPPIN G, et al . Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes[J ] . Diabetes Care, 2014, 37(7):1815-1823. DOI: 10.2337/dc13-3055.

HADJADJ S, ROSENSTOCK J, MEINICKE T, et al . Initial combination of empagliflozin and metformin in patients with type 2 diabetes[J ] . Diabetes Care, 2016, 39(10):1718-1728. DOI: 10.2337/dc16-0522.

JI L, LI H, MANSFIELD T A, et al . Dapagliflozin as monotherapy in drug-naive asian patients with type 2 diabetes mellitus: a randomized, blinded, prospective phase Ⅲ study[J ] . Clin Ther, 2014, 36(1):84-100. DOI: 10.1016/j.clinthera.2013.11.002

FERRANNINI E, RAMOS S J, SALSALI A, et al . Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial[J ] . Diabetes Care, 2010, 33(10):2217-2224. DOI: 10.2337/dc10-0612.

ROSENSTOCK J, HANSEN L, ZEE P, et al . Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: a randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin[J ] . Diabetes Care, 2015, 38(3):376-383. DOI: 10 .2337/dc14-1142.

BAILEY C J, GROSS J L, HENNICKEN D, et al . Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial[J ] . BMC Med, 2013, 11:43. DOI: 10.1186/1741-7015-11-43.

FRÍAS J P, GUJA C, HARDY E, et al . Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8):a 28 week, multicentre, double-blind, phase 3, randomised controlled trial[J ] . Lancet Diabetes Endocrinol, 2016, 4(12):1004-1016. DOI: 10.1016/S2213-8587(16)30267-4.

STROJEK K, YOON K H, HRUBA V, et al . Dapagliflozin added to glimepiride in patients with type 2 diabetes mellitus sustains glycemic control and weight loss over 48 weeks: a randomized, double-blind, parallel-group, placebo-controlled trial[J ] . Diabetes Ther, 2014, 5(1):267-283. DOI: 10.1007/s13300-014-0072-0.

JABBOUR S A, HARDY E, SUGG J, et al . Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin:a 24-week, multicenter, randomized, double-blind, placebo-controlled study[J ] . Diabetes Care, 2014, 37(3):740-750. DOI: 10.2337/dc13-0467.

BAILEY C J, IQBAL N, T'JOEN C, et al . Dapagliflozin monotherapy in drug-naïve patients with diabetes:a randomized- controlled trial of low-dose range[J ] . Diabetes Obes Metab, 2012, 14(10):951-959. DOI: 10.1111/j.1463-1326.2012.01659.x.

BOLINDER J, LJUNGGREN Ö, KULLBERG J, et al . Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin[J ] . J Clin Endocrinol Metab, 2012, 97(3):1020-1031. DOI: 10.1210/jc.2011-2260.

WILDING J P, WOO V, SOLER NG, et al . Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial[J ] . Ann Intern Med, 2012, 156(6):405-415. DOI: 10.7326/0003-4819-156-6-201203200-00003.

孙静媛, 马丽娜, 高凌.钠-葡萄糖共转运蛋白1和2的研究新进展[J].世界华人消化杂志, 2016, 24(25):3673- 3682. DOI: 10.11569/wcjd.v24.i25.3673.

SUN J Y, MA L N, GAO L. New perspectives on research of sodium-glucose cotransporters1 and 2[J]. World Chin J Diges, 2016, 24(25):3673-3682. DOI: 10.11569/wcjd.v24.i25.3673.

HALIMI S, VERGÉS B. Adverse effects and safety of SGLT-2 inhibitors[J]. Diabetes Metab, 2014, 40(6 Suppl 1):S28-34. DOI: 10.1016/S1262-3636(14)72693-X.

LI D, WANG T, SHEN S, et al . Urinary tract and genital infections in patients with type 2 diabetes treated with sodium-glucose co-transporter 2 inhibitors: A meta-analysis of randomized controlled trials[J ] . Diabetes Obes Metab, 2017, 19(3):348-355. DOI: 10.1111/dom.12825.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Efficacy and safety of autologous bone marrow stem cells transplantation for type 2 diabetes mellitus

Predictive value of TyG-BMI, AIP, and postprandial glucose excursion for sarcopenia in patients with type 2 diabetes mellitus

Influencing factors for sarcopenia in type 2 diabetes patients

Trajectory and influencing factors of fasting blood glucose fluctuations in patients with type 2 diabetes mellitus in community

Related Author

姚金萍

段炼

童强

徐梓辉

CHEN Yue¹

YU Weiwei

GAO Jin

CHEN Xingyu

Related Institution

Department of Quality Control

Department of Dermatology and Venereology

Department of Endocrinology，Jiangbei Branch/No.9, Hospital of PLA Army, First Affiliated Hospital， Army Medical University （Third Military Medical University）

Department of Endocrinology， the First Affiliated Hospital of Chongqing Medical University

Department of Pain Medicine， First Affiliated Hospital， Army Medical University （Third Military Medical University）

⁰